Akari Therapeutics Plc
No enriched coverage for $AKTX in the last 7 days.
No SEC Form 4 filings for $AKTX in the last 30 days.
See all $AKTX insider activity →Akari Therapeutics reported a Q2 2026 net loss of $4.8M, up from $1.9M a year earlier, and said it ended June 30, 2026 with $7.7M cash. The company raised about $8.6M gross proceeds (about $8.0M net) via private placement and warrant exercises. Akari is advancing AKTX-101 toward a planned mid-2027 Phase 1 start.
Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform AKTX-101 advancing through IND-enabling development activities toward planned initiation of P
Akari Therapeutics (AKTX) said it will collaborate with Whitehawk Therapeutics on preclinical studies combining Akari’s PH1 spliceosome-modulating ADC payload with Whitehawk’s TOP1 inhibitor ADC platform. Akari will lead the work to assess dual-payload compatibility and potential synergies. AKTX shares were down 15.07% to $9.10 after a 1-for-40 reverse split on March 30, 2026.
Recent AKTX coverage spans financial news, corporate actions and market movers.
The financing and updated clinical timeline for AKTX-101 are the key near-term drivers for AKTX risk and valuation.
This is a primary disclosure of interim financial results, but the scraped text does not include the actual numbers or guidance.
The deal is a preclinical, dual-payload compatibility and synergy study that could shape future development decisions for Akari’s PH1 payload.
Early-stage feline GLP-1 trial sponsorship creates a potential future catalyst, but near-term trading impact is limited by lack of topline results.
AGM resolutions include advisory compensation items and approvals for potential share/warrant issuances under Nasdaq rules, which can affect dilution expectations.
alphai scores every news story that mentions AKTX with an AI model for sentiment and relevance, and aggregates insider trades from Akari Therapeutics Plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Akari Therapeutics reported a Q2 2026 net loss of $4.8M, up from $1.9M a year earlier, and said it ended June 30, 2026 with $7.7M cash. The company raised about $8.6M gross proceeds (about $8.0M net) via private placement and warrant exercises. Akari is advancing AKTX-101 toward a planned mid-2027 Phase 1 start.
1 min readAkari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform AKTX-101 advancing through IND-enabling development activities toward planned initiation of P
2 min readAkari Therapeutics (AKTX) said it will collaborate with Whitehawk Therapeutics on preclinical studies combining Akari’s PH1 spliceosome-modulating ADC payload with Whitehawk’s TOP1 inhibitor ADC platform. Akari will lead the work to assess dual-payload compatibility and potential synergies. AKTX shares were down 15.07% to $9.10 after a 1-for-40 reverse split on March 30, 2026.
3 min readTwo U.S. biotech firms, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats. Akston is sponsoring a Cornell study of about 70 cats, while OKAVA is trialing a long-acting implant for up to six months. The drugs are unapproved and results are expected later this year.
6 min readAkari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001541157 0001541157 2026-06-30 2026-06-30 0001541157 AKTX:AmericanDepositarySharesEachRepresenting80000OrdinarySharesMember 2026-06-30 2026-06-30 0001541157 AKTX:OrdinarySharesParValue0.000000005PerShareMember 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbr
2 min readAkari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001541157 0001541157 2026-06-23 2026-06-23 0001541157 AKTX:AmericanDepositorySharesEachRepresenting80000OrdinarySharesMember 2026-06-23 2026-06-23 0001541157 AKTX:OrdinarySharesParValue0.000000005PerShareMember 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbr
4 min readAkari Therapeutics (NASDAQ:AKTX) saw short interest rise to 64,685 shares as of May 15, up from 16,135 on April 30, with about 8.2% of shares sold short and a short-interest ratio of 1.8 days. Armistice Capital bought 2,723,966 shares in Q4, valuing the stake at ~$787,000 (5.95%). Analysts’ consensus is “Hold” with a $89 target. The stock traded at $16.43; EPS missed on May 20.
4 min readSciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.
6 min readAkari Therapeutics (NASDAQ: AKTX) announced that its President and CEO, Abizer Gaslightwala, will participate in an investor webcast on May 20, 2026, to discuss the company's differentiated antibody drug conjugate (ADC) pipeline. The presentation will focus on its proprietary PH1 RNA splicing modulator payload platform and the lead TROP2-targeting ADC program, AKTX-101. The event is virtual, with registration available online.
3 min readThis page provides the debt to equity ratio for Akari Therapeutics Plc Sponsored ADR, traded under the symbol CLA1 on the Munich Stock Exchange. It is part of a financial overview for the company, accessible through TradingView. The content primarily displays the financial metric without further descriptive analysis or historical data on this specific page.
1 min read
